While Democrats and the corporate media have fixated on the stock market in recent weeks, they’ve largely ignored the even more important economic trend that is redefining the country’s future – trillions of dollars in new investment in the United States thanks to President Donald Trump’s bold trade, energy, and regulatory agenda.

Just this week, technology giant Nvidia announced that it will be manufacturing AI supercomputers in the United States for the first time. The company says it plans to build more than one million square feet of warehouse space for the endeavor.

Just hours after that announcement, Japanese vehicle manufacturer Honda also confirmed that it plans to expand U.S. vehicle production by as much as 30 percent to avoid Trump’s tariffs on auto imports – a clear example of the tariffs working as intended. Honda’s next-generation Civic hybrid, which was initially slated to be produced in Mexico, will now be made in Indiana.

The number of companies making major announcements like these is growing by the day and began before Trump even took office in January. “We have, I would say, more than $7 trillion now… of investments coming in,” Trump said during a press conference on April 9. “Apple is coming in for $500 billion alone. We have other companies coming in with massive numbers.”

As Trump alluded to, Apple has made one of the biggest investments in America to date. CEO Tim Cook said the company is “bullish” on the United States and that he foresees the $500 billion investment as part of “an extraordinary new chapter in the history of American innovation.”

“From doubling our Advanced Manufacturing Fund, to building advanced technology in Texas, we’re thrilled to expand our support for American manufacturing,” Cook announced. The company specifically plans to build “a new advanced manufacturing facility in Houston to produce servers that support Apple Intelligence” as well as a new “academy in Michigan to train the next generation of U.S. manufacturers.” It will also invest in research and development projects.

Meanwhile, Japanese company SoftBank pledged last December to invest $100 billion in the United States. As noted by the Associated Press, this is double the $50 billion investment promised following Trump’s first victory in 2016. “This is the beginning of [a] golden age,” CEO Masayoshi Son stated in January 2025, following the announcement of a $500 billion artificial intelligence investment fund involving SoftBank, Open AI, and Oracle.

Following Trump’s threats to place tariffs on semiconductor chips, Taiwan Semiconductor Manufacturing Company (TSMC) also committed to a $100 billion investment in March, as reported by Newsweek.

“The new TSMC investments will fund three new chip fabrication plants, two advanced packaging facilities, and a new research and design center,” Newsweek reported. “This brings the company’s total investment in Phoenix, Arizona, to $165 billion – the largest foreign direct investment in U.S. history.”

Chairman C.C. Wei directly cited Trump’s first term in office as the catalyst behind the major investment. “Back in 2020, thanks to President Trump’s vision and support, we embarked on our journey of establishing advanced chip manufacturing in the United States. This vision is now a reality,” he stated in a news release.

The investment is expected to create tens of thousands of construction jobs in the short run and similar amounts of tech manufacturing jobs in the long run.

But it’s not just consumer products that will soon be manufactured in the United States instead of abroad. Swiss pharmaceutical company Novartis has also unveiled plans to invest $23 billion in new American facilities. The company specifically “plans to build six new manufacturing plants, some of which will make raw pharmaceutical ingredients, as well as a new research and development site in San Diego, California” and expand several other facilities, according to an April 10 report from Reuters.

Novartis CEO Vas Narasimhan directly attributed the announcement to a positive “regulatory environment” brought on by Trump’s return to the Oval Office. “These investments reflect the pro-innovation policy and regulatory environment in the U.S. that supports our ability to find the next medical breakthroughs for patients,” Narasimhan stated.

In fact, so many pharmaceutical companies are investing in the United States that European companies are reportedly concerned about a massive “exodus,” as corporations look to relocate to America. “E.U. pharma firms have called on the European Commission president, Ursula von der Leyen, to push for ‘rapid and radical action’ to mitigate the ‘risk of exodus’ to the US after a meeting in Brussels,” The Guardian reported.

American pharmaceutical companies are also planning to reinvest at home; in March, Johnson & Johnson “announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years.”

Company leaders said President Trump’s first term in office, particularly the 2017 Tax Cuts and Jobs Act, played a role in their decision.

Planned investments include “a high-tech facility in North Carolina,” and “three new advanced manufacturing facilities,” according to a company news release. Johnson & Johnson will also expand “several existing sites across the Company’s Innovative Medicine and MedTech businesses.”

The new North Carolina facility will employ 5,000 construction workers and 500 permanent positions, the company announced.

“President Trump will stop at nothing to restore American manufacturing and bring jobs back where they belong — right here in the U.S.,” the White House stated in a news release.

The ongoing investments show that companies are optimistic about a revival in American manufacturing and the continued growth of the economy – despite some temporary downturns in the stock market. Trump’s plans to revitalize American industry are already paying off and are set to continue to generate even greater returns for decades to come.

Matt Lamb is an AMAC Newsline Contributor and an associate editor for The College Fix. He previously worked for Students for Life of America, Students for Life Action, and Turning Point USA. He previously interned for Open the Books. His writing has also appeared in the Washington Examiner, The Federalist, LifeSiteNews, Human Life Review, Headline USA, and other outlets. The opinions expressed are his own. Follow him @mattlamb22 on X.